clinicaltrials

Explore "clinicaltrials" with insightful episodes like "The Cure", "Uber earnings + using AI to revolutionize clinical trials w/ Unlearn.AI’s Charles Fisher | E1734", "How Well Does A New Alzheimer's Drug Work For Those Most At Risk?", "Leaked Moderna Files with Sasha Latypova" and "'Some Hope Is Better Than Having No Hope'" from podcasts like ""Movers and Shakers: a podcast about life with Parkinson's", "This Week in Startups", "Short Wave", "RFK Jr Podcast" and "The Daily"" and more!

Episodes (11)

The Cure

The Movers and Shakers are back in the Notting Hill pub, and this week we're talking about quite possibly the biggest question in the world of Parkinson's: will we get a cure? To assist with answering this ultimate enquiry, the gang are joined by Prof Tom Foltynie, a neurologist at the bleeding edge of PD research, and Will Cook, CEO of the aptly named charity Cure Parkinson's. Is there hope for a cure? What form could it take? And what timeframe might we see it in?

Presented by Rory Cellan-Jones, Gillian Lacey-Solymar, Mark Mardell, Paul Mayhew-Archer, Sir Nicholas Mostyn, and Jeremy Paxman.

Produced and edited by Nick Hilton for Podot.

Additional editing by Ewan Cameron.

Music by Alex Stobbs.

Artwork by Till Lukat.

PR by Sally Jones.

Movers and Shakers is generously sponsored by Boardwave, high powered Executive networking programme for European Software CEO, Non-Exec Directors, Chairs and their Investors. They are keen supporters of Cure Parkinson's. To find out more, visit https://cureparkinsons.org.uk/

Hosted on Acast. See acast.com/privacy for more information.

Movers and Shakers: a podcast about life with Parkinson's

enMay 27, 2023

Uber earnings + using AI to revolutionize clinical trials w/ Unlearn.AI’s Charles Fisher | E1734

First up, Jason breaks down Uber’s huge Q1 results! (1:21) Then, Unlearn.AI CEO Charles Fisher joins to discuss the advancements his company is making in fast-tracking clinical trials (9:49), how machine learning is used in drug development (16:24), Unlearn’s business model (35:24), and more!

(0:00) Jason kicks off the show

(1:21) Uber’s Q1 earnings

(8:31) QuickNode - Get one month free by using code TWIST at https://go.quicknode.com/twist

(9:49) The foundation of Unlearn.AI

(12:42) Unlearn.AI’s impact on the clinical trial process

(14:24) Criticisms of the current clinical trial model

(16:24) ML’s Impact on drug discovery

(24:16) CacheFly - Get 10 terabytes free by signing up at https://twist.cachefly.com

(25:42) The data used in the medical system today

(34:05) Microsoft for Startups Founders Hub - Apply in 5 minutes for six figures in discounts at http://aka.ms/thisweekinstartups

(35:24) Unlearn.AI’s business model

(40:22) Building a foundational model for health

(44:06) The pace of AI today vs. the previous decade

(46:35) More on Unlearn.AI’s business model

(48:15) Creating foundational datasets in health

FOLLOW Charles: https://twitter.com/charleskfisher

FOLLOW Jason: https://linktr.ee/calacanis

Subscribe to our YouTube to watch all full episodes:

https://www.youtube.com/channel/UCkkhmBWfS7pILYIk0izkc3A?sub_confirmation=1

FOUNDERS! Subscribe to the Founder University podcast:

https://podcasts.apple.com/au/podcast/founder-university/id1648407190

This Week in Startups

en-usMay 03, 2023

How Well Does A New Alzheimer's Drug Work For Those Most At Risk?

A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough to definitively say if the drug is effective for Black people. "[In] the world's most diverse Alzheimer's trial, a giant trial of 1,800 people that lasted for a much longer time than most trials did, we're still not sure that all of the groups that are at highest risk of Alzheimer's disease actually see any kind of benefit," says Dr. Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School.

On today's episode, Jonathan and Short Wave co-host Emily Kwong delve into how drug developers can overlook those hardest hit by the disease they're trying to treat.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

en-usMarch 13, 2023

alzheimersdrugresearch

Leaked Moderna Files with Sasha Latypova

Sasha Latypova discusses leaked Moderna files showing FDA Colluded With Moderna.

According to Sasha Latypova, an ex-pharmaceutical industry executive, documents obtained from the U.S. Department of Health and Human Services on Moderna’s COVID-19 vaccine suggest the U.S. Food and Drug Administration and Moderna colluded to bypass regulatory and scientific standards used to ensure products are safe.

--- Send in a voice message: https://podcasters.spotify.com/pod/show/rfkjr/message

enAugust 04, 2022

'Some Hope Is Better Than Having No Hope'

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.

What is the story behind this new drug?

Guest: Pam Belluck, a health and science writer for The New York Times.

Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.

Background reading:

Aduhelm, also known as aducanumab, was approved despite opposition from the F.D.A.’s independent advisory committee and some Alzheimer’s experts.
Even those who supported the F.D.A.’s approval have said that authorizing it for anyone with the disease is much too broad.

For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

enJuly 07, 2021

Psilocybin Therapy - Part 2: Clinical Trials, Secondary Effects, Brain Imaging, and the Future of Psilocybin Therapy

With the background from part 1 in mind, in part 2, we review the modern era of research exploring the treatment of various psychopathology. The results for these studies begin to elucidate the various effects individuals experience with psilocybin. The benefits are potentially impressive, however, there are significant limitations that are noteworthy. Psilocybin therapy is just coming out of its nascence and it is useful to have a critical view of the research coming out to avoid pitfalls in the future.

Link to Blog.

Link to Resource Library.

Psychiatry & Psychotherapy Podcast

aaJanuary 05, 2021

psilocybintherapypart2

secondaryeffects

COVID-19 Chapter 13: Vaccines, Take 2

We’re back with another episode in our Anatomy of a Pandemic series on COVID-19. This time, our subject matter is the one everyone has been waiting for: vaccines. In this episode, with the help of two amazing guests, we attempt to answer all of your burning questions about the new vaccines for the virus that causes COVID-19. We walk you through the ins and outs of the technology behind these vaccines, the safety and regulation steps required for their approval, and some of the logistical challenges involved in their distribution. For this info-packed episode, we were so fortunate to be joined by Dr. Maria Sundaram (interview recorded Dec 14, 2020), postdoctoral fellow at the University of Toronto Center for Vaccine Preventable Diseases and fellow at ICES and Dr. Orin Levine (interview recorded Nov 24, 2020), Director of Vaccine Delivery at the Bill and Melinda Gates Foundation. As always, we wrap up the episode by discussing the top five things we learned from our experts. If at the end of this interview, your curiosity about vaccines is not quite satisfied, check out the COVID-19 Vaccine Tracker website, which is an incredible resource for pretty much anything you could ever want to know about these vaccines. To help you get a better idea of the topics covered in this episode, we’ve listed the questions below: Can you break down what the three potentially successful COVID-19 vaccines are and how each of them work? What are in these vaccines? What are the ingredients and what do they do? There has been some misunderstanding that these vaccines have the potential to give you COVID-19. Can you explain why that isn’t possible? Why are people being advised to wear a mask even after getting vaccinated? What does the timeline look like for these vaccines until we can go to the doctor or pharmacy and get one? Is it a valid concern that this vaccine was developed so rapidly? And could you walk us through some of the steps being taken to ensure safety and efficacy of a vaccine? Can you talk about what emergency use authorization means and whether we’ve seen this before and under what circumstances? Why should people be no more scared of this vaccine than the usual vaccines, like MMR and seasonal influenza? How likely is it that additional side effects we haven’t yet seen or long-term side effects will emerge later on? What do we know about the risk of vaccine-induced antibody-dependent enhancement with this vaccine? What do we know so far about the efficacy of these vaccines? Can you walk us through efficacy vs effectiveness in terms of vaccines? What do we know so far about how long immunity is expected to last from the various vaccines that are close to completion? What are some of the issues with clinical trials in vaccine development in terms of getting a representative subsection of the population and what does this mean for who may be able to get a vaccine once one is ready? Why do you still need to get vaccinated even if you’ve already had COVID-19? For our listeners who may know someone who is hesitant to receive the vaccine, what advice or reassurance can you give them that choosing to get one of these vaccines is a better option than taking your chances with COVID-19? What are the biggest hurdles to vaccine distribution here in the US? What are the biggest hurdles in terms of global distribution of the vaccine? And what is being done to address some of these challenges in vaccine access? We’ve heard about some countries pre-purchasing large stocks of vaccines, how may that affect the global availability especially in lower income countries? How might the availability of several different successful COVID-19 vaccines affect how different countries build their vaccine supply or distribution chain? Could you talk about how skepticism surrounding vaccines plays into not only vaccine development but administration, and what can be done to rebuild trust in those communities? How do you think this pandemic will change the way that we view either emerging infectious diseases or vaccines in the future? Learn more about your ad choices. Visit megaphone.fm/adchoices

This Podcast Will Kill You

enDecember 22, 2020

Episode 98 - Dr. Stephen Sample: Blue Doc in a Red State

Kaveh and guest co-host Ryan Marino talk to Dr. Stephen Sample (otherwise known as Dr. JAFERD) about his path from county music singer to Air Force to MSNBC/CNN medical contributor and his transition politically.Send your questions and comments to hopquestions@gmail.com, or leave a voicemail at 408-444-6623

Hosted on Acast. See acast.com/privacy for more information.

The House of Pod: A Medical Podcast

enNovember 18, 2020

We ask a biostatistician about the timeline of a COVID-19 vaccine

There’s a lot of information coming and going about the coronavirus, and the next steps for vaccines and treatments for COVID-19 — The Verge even has a newsletter dedicated to it. But how do we asses all this information in a logical way, to prevent confusion, chaos, or something worse? The Verge’s Nilay Patel, Mary Beth Griggs and Nicole Wetsman talked to Dr. Natalie Dean, assistant professor of biostatistics at the University of Florida, about what we know so far about the timeline of a COVID-19 vaccine, and the best way to evaluate the flood of information coming in every day. We are conducting an audience survey to better serve you. It takes no more than five minutes, and it really helps out the show. Please take our survey here: voxmedia.com/podsurvey. Learn more about your ad choices. Visit podcastchoices.com/adchoices

enSeptember 15, 2020

Coronavirus: Dude, Where's My Vaccine?

All through the pandemic, we’ve been waiting for a possible silver bullet: a vaccine. How soon could we actually get one? To find out, we talk to microbiologist and immunologist Professor Karla Satchell, immunologist Dr. Kathryn Stephenson, Pfizer executive Mike McDermott, and Ian Haydon, who’s participating in a vaccine clinical trial. Here’s a link to our transcript: https://bit.ly/3egWFrc This episode was produced by Wendy Zukerman, with help from Michelle Dang, Sinduja Srinivasan, Laura Morris, Meg Driscoll, Rose Rimler, Meryl Horn, and Mathilde Urfalino. We’re edited by Blythe Terrell with help from Caitlin Kenney. Fact checking by Lexi Krupp. Mix and sound design by Peter Leonard. Music written by Peter Leonard, Marcus Bagala, Emma Munger, and Bobby Lord. A huge thanks to all the researchers we got in touch with for this episode, including Dr. Barney Graham, Dr. Melvin Sanicas, Dr. Norbert Pardi, Professor Peter Waterhouse, Professor Edward Mocarski, Dr. Ramin Herati, Dr. Rachel Roper, and Dr. Yvonne Genzel. And special thanks to the Zukerman family and Joseph Lavelle Wilson. Learn more about your ad choices. Visit podcastchoices.com/adchoices

enJune 19, 2020

neutralizingantibodies

parasiticrelationships

That Revolutionary Gene-Editing Experiment? So Far So Good.

Earlier this month NPR health correspondent Rob Stein introduced us to Victoria Gray, the woman at the center of a groundbreaking medical treatment using CRISPR, the gene-editing technique. This week, Rob reports exclusively for NPR on the first results of that closely-watched experiment. Follow host Maddie Sofia on Twitter @maddie_sofia. Email the show at shortwave@npr.org.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

Short Wave

en-usNovember 20, 2019